Zoliflodacin is a clinical-stage drug being developed for the treatment of Uncomplicated gonorrhea is a common sexually transmitted bacterial infection caused by Neisseria gonorrhoeae (N. gonorrhoeae) that primarily affects the mucosal surfaces of the urogenital, rectal, or pharyngeal tract without evidence of systemic spread or inflammatory complications. Uncomplicated gonorrhea typically presents with urethral discharge, dysuria, cervical inflammation, or rectal or pharyngeal symptoms, though many individuals experience no symptoms at all. It is estimated 1,568,000 new N. gonorrhoeae infections occur each year in US (1). Despite being “uncomplicated,” the condition imposes a substantial public-health burden, contributing to persistent transmission, increased susceptibility to HIV, and risk of progression to pelvic inflammatory disease, epididymitis, or disseminated gonococcal infection if left untreated.. It is being developed by Innoviva Inc.. The FDA Prescription Drug User Fee Act (PDUFA) date is December 14, 2025. Premium analysis including detailed clinical trial status, revenue predictions, and comprehensive company insights are available for members.